Cargando…
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
OBJECTIVE: The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated f...
Autores principales: | Monane, Mark, Johnson, Kim G., Snider, B. Joy, Turner, Raymond S., Drake, Jonathan D., Maraganore, Demetrius M., Bicksel, James L., Jacobs, Daniel H., Ortega, Julia L., Henderson, Joni, Jiang, Yan, Huang, Shuguang, Coppinger, Justine, Fogelman, Ilana, West, Tim, Braunstein, Joel B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578891/ https://www.ncbi.nlm.nih.gov/pubmed/37550958 http://dx.doi.org/10.1002/acn3.51863 |
Ejemplares similares
-
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology
por: Fogelman, Ilana, et al.
Publicado: (2023) -
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011) -
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
por: West, Tim, et al.
Publicado: (2021) -
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
por: Hu, Yan, et al.
Publicado: (2022) -
Meta-Analysis in Genome-Wide Association Datasets: Strategies and Application in Parkinson Disease
por: Evangelou, Evangelos, et al.
Publicado: (2007)